Esperion Therapeutics, Inc. (ESPR) Financials

ESPR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 462.5 million 770.5 million
Dec. 31, 2025 465.9 million 767.9 million
Sept. 30, 2025 364.0 million 815.4 million
June 30, 2025 347.1 million 780.6 million

ESPR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -27.9 million 2.5 million
Dec. 31, 2025 45.4 million 2.4 million
Sept. 30, 2025 -4.3 million 2.3 million
June 30, 2025 -31.4 million 2.7 million

ESPR Net Income

No data available :(

ESPR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 156.2 million 250.9 million 861000
Dec. 31, 2025 167.9 million 457.6 million 653000
Sept. 30, 2025 92.4 million 448.1 million 3.2 million
June 30, 2025 86.1 million 473.1 million 4.1 million

ESPR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 251.4 million
Dec. 31, 2025 284.6 million
Sept. 30, 2025 198.2 million
June 30, 2025 196.8 million

ESPR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 189000 9.0 million 43.1 million -
Dec. 31, 2025 189000 13.9 million 41.4 million -
Sept. 30, 2025 - 14.1 million 41.8 million -
June 30, 2025 - 7.2 million 39.5 million -

ESPR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 80.1 million 34.6 million
Dec. 31, 2025 168.4 million 27.9 million
Sept. 30, 2025 87.3 million 55.4 million
June 30, 2025 82.4 million 28.5 million

ESPR Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ESPR

Price: $3.13

52 week price:
0.69
4.18

Earnings Per Share: -0.11 USD

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 623424

Ebitda: -37.8 million

Market Capitalization: 805.8 million

Links: